The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Lamisil AT Cream



GlaxoSmithKline Consumer Healthcare (Ireland) LimitedPA0678/121/002

Main Information

Trade NameLamisil AT Cream
Active SubstancesTERBINAFINE HYDROCHLORIDE
Dosage FormCream
Licence HolderGlaxoSmithKline Consumer Healthcare (Ireland) Limited
Licence NumberPA0678/121/002

Group Information

ATC CodeD01AE Other antifungals for topical use
D01AE15 terbinafine

Status

License statusAuthorised
Licence Issued24/01/2003
Legal statusProduct not subject to medical prescription
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to the general public
Conditions of LicenceRetail sales through pharmacies subject to the following restrictions: maximum strength: 1.0%, maximum pack size: 15g, maximum period of treatment: 14 days, products other than spray solutions, limited indications: treatment of tinea cruris (jock or dhobie itch) and tinea pedis (athlete's foot), use in adults and children over 16 years.
Marketing StatusMarketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back